<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82956">
  <stage>Registered</stage>
  <submitdate>2/07/2008</submitdate>
  <approvaldate>16/07/2008</approvaldate>
  <actrnumber>ACTRN12608000336381</actrnumber>
  <trial_identification>
    <studytitle>An Open-label Phase I Study of the Safety and Efficacy of MDX-1097 in the Treatment of Previously Treated Kappa Light Chain Restricted Multiple Myeloma Patients with Stable Measurable Disease</studytitle>
    <scientifictitle>An Open-label Phase I Study of the Safety and Efficacy of MDX-1097, an human IgG1k chimeric monoclonal antibody, in the Treatment of Previously Treated Kappa Light Chain Restricted Multiple Myeloma Patients with Stable Measurable Disease to determine the Safety, Tolerability and Maximum Tolerated Dose</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Multiple myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Myeloma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a Phase I study of MDX-1097 an IgG1k chimeric monoclonal antibody. Up to 30 previously treated multiple myeloma patients with stable measurable disease will be enrolled in the study. Five dose levels are planned: 0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 10 mg/kg and 30 mg/kg per dose will be administered as a single intravenous infusion. Patients will be assigned to a dose level in the order of study entry.</interventions>
    <comparator>No comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the safety and tolerability of MDX-1097. Adverse events are graded using the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE), Version 3. Comparison of vital sign measurements, physical examination assessments, Eastern Cooperative Oncology Group (ECOG) performance assessments, 12 lead electrocardiogram (ECG), clinical laboratory tests for haematology, clinical chemistry, urinalysis and creatinine clearance and changes in concomitant therapy from screening phase (baseline) to study completion (day 45)</outcome>
      <timepoint>Patients will be observed for 45 days post a single intravenous dose for any adverse event.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the maximum tolerated dose of MDX-1097.</outcome>
      <timepoint>Dose limiting toxicities will be observed for 2 weeks post a single infusion.
&gt;Grade 3 non-hematological toxicity excluding tumor flare
&gt;Grade 4 Hematological toxicity
&gt;Grade 4 infusion toxicity</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of kappa light chain restricted multiple myeloma with stable measurable disease.
Serum paraprotein of &gt; 5 g/L, 24 hour urinary light chain excretion of &gt; 200 mg, or demonstration of excess serum free kappa light chains and an abnormal kappa:lambda light chain ratio.
Patients on maintenance therapy for multiple myeloma</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Non-measurable disease by serological measurement, serum free kappa light chains &gt; 250 mg/L, active infections, pregnant or lactating women, any other active malignancy, patients on other investigational agents.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>4/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Immune System Therapeutics</primarysponsorname>
    <primarysponsoraddress>Level 8, UTS Building 10
235 Jones Street
Ultimo NSW 2007</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Immune System Therapeutics</fundingname>
      <fundingaddress>Level 8, UTS Building 10
235 Jones Street
Ultimo NSW 2007</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase I study is a single-center, open-label, between-patient, single ascending dose study intended to determine the safety, tolerability and maximum tolerated dose (MTD) of MDX-1097.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital Drugs and Interventions Committee</ethicname>
      <ethicaddress>The Alfred Hospital
Commercial Road
Melbourne</ethicaddress>
      <ethicapprovaldate>1/04/2008</ethicapprovaldate>
      <hrec>267/07</hrec>
      <ethicsubmitdate>19/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Andrew Spencer</name>
      <address>Myeloma Research Group, The Alfred hospital, Commercial Road, Melbourne, VIC3004</address>
      <phone>+61 3 90763393</phone>
      <fax>+61 3 90762298</fax>
      <email>aspencer@netspace.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kate Reed</name>
      <address>Myeloma Research Group Alfred Hospital
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 92763571</phone>
      <fax />
      <email>K.Reed@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Rosanne Dunn</name>
      <address>Level 8, UTS Building 10
235 Jones Street
Ultimo NSW 2007</address>
      <phone>+61 2 95144060</phone>
      <fax>+61 2 95147436</fax>
      <email>rdunn@istl.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>